Page URL:

Diabetes 'breakthrough' as insulin-producing cells formed in lab

13 October 2014
Appeared in BioNews 775

Millions of insulin-producing beta cells have been manufactured in the laboratory using human stem cells by scientists at Harvard University.

Tests on mice with type 1 diabetes showed that these lab-made cells could treat the disease for several months as they produced insulin and subsequently controlled blood sugar levels.

'If this scalable technology is proven to work in both the clinic and in the manufacturing facility, the impact on the treatment of diabetes will be a medical game-changer on a par with antibiotics and bacterial infections,' commented Chris Mason, professor of regenerative medicine at University College London, who was not involved in the study.

Overall the researchers screened about 150 different combinations of chemical growth factors, which had been previously described in playing a role in pancreatic biology. They found that combining 11 of these chemicals could transform embryonic stem cells into functioning beta cells – cells which make the insulin hormone within the pancreas.

People with type 1 diabetes, which affects about 400,000 people in Britain, lack beta cells because their own immune system destroys them.

'There have been previous reports of other labs deriving beta cell types from stem cells, [but] no other group has produced mature beta cells as suitable for use in patients,' said lead author of the study Professor Doug Melton.

He added: 'The biggest hurdle has been to get to glucose-sensing, insulin-secreting beta cells, and that's what our group has done.'

Professor Melton started the research 23 years ago after his son Sam was diagnosed with type 1 diabetes. 'He hopes to have human transplantation trials using the cells under way within a few years,' reports the University of Harvard press release.

Treatment for diabetes using beta cell transplantation remains in the experimental stages. It uses cells from cadavers that are in limited supply, it requires the use of powerful immunosuppressive drugs, and is available to only a very small number of patients.

Dr Gillian Morrison at the University of Edinburgh told the BBC that this 'represents a real advance in the field'. She added: 'The next important challenge will be to find ways to maintain these cells inside the body so they are protected from the immune response and have long-term function.'

Besides offering a new form of treatment for type 1 diabetes, the scientists believe it could also offer hope for the people with type 2 diabetes who have to rely on regular insulin injections.

The research was published in the journal Cell.

18 April 2016 - by Paul Waldron 
Two new studies report the creation of functioning human beta cells, which can release insulin in response to changes in blood sugar, holding promise for the treatment of diabetes...
3 November 2014 - by Antony Starza-Allen 
Scientists in the USA have for the first time created three-dimensional stomach tissue from human pluripotent stem cells...
27 October 2014 - by Siobhan Chan 
A section of functioning human intestine has been transplanted into mice, giving scientists a new model with which to study intestinal diseases...
6 May 2014 - by Dr Gabrielle Samuel 
Researchers have transformed embryonic stem cells from a diabetic woman into insulin-producing beta cells, a study in Nature reports...
10 February 2014 - by Chris Hardy 
Stem cells have reversed the equivalent of type 1 diabetes in genetically modified mice. Using skin cells as a starting point, researchers formed pancreas precursor cells that produced insulin when injected into mice...
13 January 2014 - by Dr Shanya Sivakumaran 
Scientists have identified mutations in two genes that cause neonatal diabetes, a rare condition affecting around 1 in 100,000 births...
11 March 2013 - by Reuben Harwood 
Genetic analysis of a family predisposed to type 1 diabetes (T1D) has uncovered the first kind of T1D to be caused by a single gene mutation...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.